Zoetis (ZTS) Income from Non-Controlling Interests (2012 - 2024)

Zoetis' (ZTS) quarterly Income from Non-Controlling Interests came in at $10.0 million in Q3 2024, up 600.0% on a QoQ basis from -$2.0 million in Q4 2023.

Zoetis (ZTS) Income from Non-Controlling Interests (2012 - 2024) Analysis & Trends

Zoetis (ZTS) has 12 years of Income from Non-Controlling Interests data on file, last reported at $10.0 million in Q3 2024.

  • On a quarterly basis, Income from Non-Controlling Interests changed N/A year-over-year to $10.0 million in Q3 2024; TTM through Jun 2025 was $10.0 million, a 600.0% increase from a year earlier, with the FY2024 full-year figure at $10.0 million, up 350.0% from the prior year.
  • Income from Non-Controlling Interests for Q3 2024 stood at $10.0 million, up from -$2.0 million in the prior quarter.
  • Over the last five years, Income from Non-Controlling Interests for ZTS reached as high as $10.0 million in Q3 2024 and fell as low as -$2.0 million in Q4 2023.
  • Historically, Income from Non-Controlling Interests has averaged -$166666.7 across 5 years, with a median of -$1.0 million in 2020.
  • Across the five-year window, Income from Non-Controlling Interests changed 0.0% in 2021 and sank 100.0% in 2023, its largest moves.
  • Year by year, Income from Non-Controlling Interests stood at -$1.0 million in 2020, then changed by 0.0% to -$1.0 million in 2021, then changed by 0.0% to -$1.0 million in 2022, then sank by 100.0% to -$2.0 million in 2023, then jumped by 600.0% to $10.0 million in 2024.
  • Per Business Quant data, the three most recent Income from Non-Controlling Interests figures were $10.0 million in Q3 2024, -$2.0 million in Q4 2023, and -$1.0 million in Q2 2023.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Inc. Minority (Qtr)
1 Haleon 89.28 Bn 87.42 Bn - -
2 Teva Pharmaceutical Industries 35.97 Bn 32.23 Bn 1.97 Bn -
3 Zoetis 32.42 Bn 30.48 Bn 1.62 Bn -
4 Takeda Pharmaceutical 27.48 Bn 23.42 Bn 4.39 Bn 395,346.10
5 United Therapeutics 22.89 Bn 20.73 Bn 648.10 Mn -
6 RedHill Biopharma 22.11 Bn 22.11 Bn - -
7 Viatris 20.44 Bn 18.64 Bn 1.16 Bn -
8 Neurocrine Biosciences 17.76 Bn 16.44 Bn 800.70 Mn -12.70 Mn
9 Elanco Animal Health 12.62 Bn 12.19 Bn 785.00 Mn -
10 Vireo Growth 10.51 Bn 10.36 Bn 59.30 Mn 3.60 Mn

Historic Data

Download Data
DateValue
Sep 30, 2024 10.00 Mn
Dec 31, 2023 -2.00 Mn
Jun 30, 2023 -1.00 Mn
Mar 31, 2023 -1.00 Mn
Dec 31, 2022 -1.00 Mn
Sep 30, 2022 -1.00 Mn
Mar 31, 2022 -1.00 Mn
Dec 31, 2021 -1.00 Mn
Jun 30, 2021 -1.00 Mn
Mar 31, 2021 -1.00 Mn
Dec 31, 2020 -1.00 Mn
Jun 30, 2020 -1.00 Mn
Jun 30, 2018 -2.00 Mn
Mar 31, 2018 -2.00 Mn
Dec 31, 2017 -1.00 Mn
Oct 1, 2017 -2.00 Mn
Apr 2, 2017 1.00 Mn
Oct 2, 2016 -2.00 Mn
Dec 31, 2015 -2.00 Mn
Sep 27, 2015 1.00 Mn